{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:55:34Z","timestamp":1766138134290},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00393-022-01283-5","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T09:06:04Z","timestamp":1667984764000},"page":"811-828","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nephrologisches Management und Medikamentendosierung bei Rheumapatienten mit Niereninsuffizienz"],"prefix":"10.1007","volume":"81","author":[{"given":"Stefan M.","family":"Weiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"1283_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/BOR.0000000000000500","volume":"30","author":"N Abdulaziz","year":"2018","unstructured":"Abdulaziz\u00a0N, Shah\u00a0AR, Mccune\u00a0WJ (2018) Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 30:249\u2013255","journal-title":"Curr Opin Rheumatol"},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, Joseph\u00a0A, Anker\u00a0SD et al (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J\u00a0Am Soc Nephrol 33:225\u2013237","journal-title":"J Am Soc Nephrol"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal\u00a0R, Sinha\u00a0AD, Cramer\u00a0AE et\u00a0al (2021) Chlorthalidone for hypertension in advanced chronic kidney disease. N\u00a0Engl J Med 385:2507\u20132519","journal-title":"N Engl J Med"},{"key":"1283_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143:337\u2013349","journal-title":"Circulation"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","volume":"42","author":"Anonymous","year":"2003","unstructured":"Anonymous (2003) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1\u2013201","journal-title":"Am J Kidney Dis"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Anonymous","year":"2017","unstructured":"Anonymous (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"1283_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Anonymous","year":"2020","unstructured":"Anonymous (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98:S1\u2013S115","journal-title":"Kidney Int"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Anonymous","year":"2021","unstructured":"Anonymous (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:S1\u2013S87","journal-title":"Kidney Int"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve\u00a0SV, Pascoe\u00a0EM, Tiku\u00a0A et\u00a0al (2020) Effects of allopurinol on the progression of chronic kidney disease. N\u00a0Engl J Med 382:2504\u20132513","journal-title":"N Engl J Med"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent\u00a0C, Landray\u00a0MJ, Reith\u00a0C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a\u00a0randomised placebo-controlled trial. Lancet 377:2181\u20132192","journal-title":"Lancet"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med 383:2219\u20132229","journal-title":"N Engl J Med"},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40620-020-00706-3","volume":"33","author":"V Binda","year":"2020","unstructured":"Binda\u00a0V, Trezzi\u00a0B, Del Papa\u00a0N et\u00a0al (2020) Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J\u00a0Nephrol 33:1019\u20131025","journal-title":"J Nephrol"},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3899\/jrheum.090153","volume":"37","author":"J Bourr\u00e9-Tessier","year":"2010","unstructured":"Bourr\u00e9-Tessier\u00a0J, Haraoui\u00a0B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a\u00a0systematic review. J\u00a0Rheumatol 37:1416\u20131421","journal-title":"J Rheumatol"},{"key":"1283_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ndt\/gfab184","volume":"37","author":"M Bozic","year":"2022","unstructured":"Bozic\u00a0M, Diaz-Tocados\u00a0JM, Bermudez-Lopez\u00a0M et al (2022) Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant 37:663\u2013672","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg\u00a0VM, Verhulst\u00a0A, Babler\u00a0A et al (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34:408\u2013414","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/ckj\/sfac014","volume":"15","author":"S Carriazo","year":"2022","unstructured":"Carriazo\u00a0S, Sarafidis\u00a0P, Ferro\u00a0CJ et al (2022) Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney\u00a0J 15:845\u2013851","journal-title":"Clin Kidney J"},{"key":"1283_CR17","doi-asserted-by":"publisher","first-page":"e22498","DOI":"10.1097\/MD.0000000000022498","volume":"99","author":"J Chen","year":"2020","unstructured":"Chen\u00a0J, Jin\u00a0Y, Li\u00a0C et al (2020) Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: a case report. Medicine 99:e22498","journal-title":"Medicine"},{"key":"1283_CR18","doi-asserted-by":"publisher","first-page":"e2645","DOI":"10.1097\/MD.0000000000002645","volume":"95","author":"CI Chou","year":"2016","unstructured":"Chou\u00a0CI, Shih\u00a0CJ, Chen\u00a0YT et al (2016) Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. Medicine 95:e2645","journal-title":"Medicine"},{"key":"1283_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/TCRM.S262843","volume":"16","author":"F Coluzzi","year":"2020","unstructured":"Coluzzi\u00a0F, Caputi\u00a0FF, Billeci\u00a0D et al (2020) Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther Clin Risk Manag 16:821\u2013837","journal-title":"Ther Clin Risk Manag"},{"key":"1283_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40620-021-01152-5","volume":"35","author":"M Cozzolino","year":"2022","unstructured":"Cozzolino\u00a0M, Minghetti\u00a0P, Navarra\u00a0P (2022) Extended-release calcifediol in stage 3\u20134 chronic kidney disease: a\u00a0new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. J\u00a0Nephrol 35:863\u2013873","journal-title":"J Nephrol"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria\u00a0A, Galecki\u00a0AT, Spino\u00a0C et\u00a0al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N\u00a0Engl J Med 382:2493\u20132503","journal-title":"N Engl J Med"},{"key":"1283_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel\u00a0P, Cunningham\u00a0J, Ferrari\u00a0S et\u00a0al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant 36:42\u201359","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","volume":"36","author":"A Godron-Dubrasquet","year":"2021","unstructured":"Godron-Dubrasquet\u00a0A, Woillard\u00a0JB, Decramer\u00a0S et al (2021) Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol 36:341\u2013347","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1283_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1463-1326.2011.01509.x","volume":"14","author":"P Hamet","year":"2012","unstructured":"Hamet\u00a0P (2012) What matters in ADVANCE and ADVANCE-ON. Diabetes Obes Metab 14(1):20\u201329","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1283_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12325-021-01939-9","volume":"39","author":"T Har\u0119\u017clak","year":"2022","unstructured":"Har\u0119\u017clak\u00a0T, Religioni\u00a0U, Szyma\u0144ski\u00a0FM et\u00a0al (2022) Drug interactions affecting kidney function: beware of health threats from triple whammy. Adv Ther 39(1):140\u2013147. https:\/\/doi.org\/10.1007\/s12325-021-01939-9","journal-title":"Adv Ther"},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink\u00a0HJL, Jongs\u00a0N, Chertow\u00a0GM et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a\u00a0prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:743\u2013754","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1283_CR27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","volume":"385","author":"CY Hsu","year":"2021","unstructured":"Hsu\u00a0CY, Yang\u00a0W, Parikh\u00a0RV et\u00a0al (2021) Race, genetic ancestry, and estimating kidney function in CKD. N\u00a0Engl J Med 385:1750\u20131760","journal-title":"N Engl J Med"},{"key":"1283_CR28","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/ndt\/gfy159","volume":"34","author":"NMA Idzerda","year":"2019","unstructured":"Idzerda\u00a0NMA, Pena\u00a0MJ, Parving\u00a0HH et al (2019) Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a\u00a0post hoc analysis of the PLANET trials. Nephrol Dial Transplant 34:1699\u20131706","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR29","doi-asserted-by":"publisher","first-page":"e0122899","DOI":"10.1371\/journal.pone.0122899","volume":"10","author":"Y Ingrasciotta","year":"2015","unstructured":"Ingrasciotta\u00a0Y, Sultana\u00a0J, Giorgianni\u00a0F et al (2015) Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a\u00a0population-based case control study. PLoS ONE 10:e122899","journal-title":"PLoS ONE"},{"key":"1283_CR30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker\u00a0LA, Eneanya\u00a0ND, Coresh\u00a0J et al (2021) New creatinine- and cystatin C\u2011based equations to estimate GFR without race. N\u00a0Engl J Med 385:1737\u20131749","journal-title":"N Engl J Med"},{"issue":"2","key":"1283_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000512585","volume":"51","author":"K Karasawa","year":"2022","unstructured":"Karasawa\u00a0K, Ogura\u00a0S, Takabe\u00a0T et al (2022) Successful treatment with belimumab in a patient with refractory systemic lupus erythematosus after initiation of hemodialysis: considering the synergistic effect of Belimumab and immunological burn-out phenomenon in end-stage renal disease patients on hemodialysis. Blood Purif 51(2):182\u2013188. https:\/\/doi.org\/10.1159\/000512585","journal-title":"Blood Purif"},{"key":"1283_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1053\/j.ajkd.2011.07.020","volume":"58","author":"J Kendrick","year":"2011","unstructured":"Kendrick\u00a0J, Chonchol\u00a0M (2011) The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 58:826\u2013834","journal-title":"Am J Kidney Dis"},{"key":"1283_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler\u00a0M, Block\u00a0GA, Evenepoel\u00a0P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"1283_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura\u00a0K, Hosoya\u00a0T, Uchida\u00a0S et\u00a0al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798\u2013810","journal-title":"Am J Kidney Dis"},{"key":"1283_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jjcc.2017.08.008","volume":"71","author":"M Kochi","year":"2018","unstructured":"Kochi\u00a0M, Kohagura\u00a0K, Shiohira\u00a0Y et\u00a0al (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J\u00a0Cardiol 71:277\u2013283","journal-title":"J Cardiol"},{"key":"1283_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jcph.178","volume":"54","author":"S Krishnaswami","year":"2014","unstructured":"Krishnaswami\u00a0S, Chow\u00a0V, Boy\u00a0M et al (2014) Pharmacokinetics of tofacitinib, a\u00a0janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J\u00a0Clin Pharmacol 54:46\u201352","journal-title":"J Clin Pharmacol"},{"key":"1283_CR37","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1007\/s10067-018-4005-6","volume":"37","author":"OC Kwon","year":"2018","unstructured":"Kwon\u00a0OC, Lee\u00a0JS, Kim\u00a0YG et al (2018) Safety of the concomitant use of methotrexate and a\u00a0prophylactic dose of trimethoprim-sulfamethoxazole. Clin Rheumatol 37:3215\u20133220","journal-title":"Clin Rheumatol"},{"key":"1283_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","volume":"40","author":"JS Lee","year":"2020","unstructured":"Lee\u00a0JS, Oh\u00a0JS, Kim\u00a0YG et al (2020) Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 40:765\u2013770","journal-title":"Rheumatol Int"},{"key":"1283_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1053\/j.ajkd.2020.12.013","volume":"78","author":"JY Lee","year":"2021","unstructured":"Lee\u00a0JY, Park\u00a0JT, Joo\u00a0YS et al (2021) Association of blood pressure with the progression of CKD: findings from KNOW-CKD study. Am J Kidney Dis 78:236\u2013245","journal-title":"Am J Kidney Dis"},{"key":"1283_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey\u00a0AS, Coresh\u00a0J, Greene\u00a0T et\u00a0al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247\u2013254","journal-title":"Ann Intern Med"},{"key":"1283_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2213-8587(15)00128-X","volume":"3","author":"JL Lu","year":"2015","unstructured":"Lu\u00a0JL, Molnar\u00a0MZ, Naseer\u00a0A et\u00a0al (2015) Association of age and BMI with kidney function and mortality: a\u00a0cohort study. Lancet Diabetes Endocrinol 3:704\u2013714","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1283_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv\u00a0J, Zhang\u00a0H, Wong\u00a0MG et\u00a0al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432\u2013442","journal-title":"JAMA"},{"key":"1283_CR43","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1055\/a-1655-4362","volume":"53","author":"HY Ma","year":"2021","unstructured":"Ma\u00a0HY, Chen\u00a0S, Lu\u00a0LL et al (2021) Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis. Horm Metab Res 53:730\u2013737","journal-title":"Horm Metab Res"},{"key":"1283_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188","journal-title":"Eur Heart J"},{"key":"1283_CR45","doi-asserted-by":"publisher","first-page":"e0192895","DOI":"10.1371\/journal.pone.0192895","volume":"13","author":"RW Major","year":"2018","unstructured":"Major\u00a0RW, Cheng\u00a0MRI, Grant\u00a0RA et al (2018) Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 13:e192895","journal-title":"PLoS ONE"},{"key":"1283_CR46","first-page":"2059364","volume":"2018","author":"CF Marlow","year":"2018","unstructured":"Marlow\u00a0CF, Sharma\u00a0S, Babar\u00a0F et\u00a0al (2018) Severe hypocalcemia and hypomagnesemia with denosumab in advanced chronic kidney disease: case report and literature review. Case Rep Oncol Med 2018:2059364","journal-title":"Case Rep Oncol Med"},{"key":"1283_CR47","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita\u00a0K, van der Velde\u00a0M, Astor\u00a0BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a\u00a0collaborative meta-analysis. Lancet 375:2073\u20132081","journal-title":"Lancet"},{"key":"1283_CR48","doi-asserted-by":"publisher","first-page":"14044","DOI":"10.1038\/boneres.2014.44","volume":"2","author":"PD Miller","year":"2014","unstructured":"Miller\u00a0PD (2014) Chronic kidney disease and the skeleton. Bone Res 2:14044","journal-title":"Bone Res"},{"key":"1283_CR49","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jcph.1375","volume":"59","author":"MF Mohamed","year":"2019","unstructured":"Mohamed\u00a0MF, Trueman\u00a0S, Feng\u00a0T et\u00a0al (2019) Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J\u00a0Clin Pharmacol 59:856\u2013862","journal-title":"J Clin Pharmacol"},{"key":"1283_CR50","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/1346-8138.15132","volume":"47","author":"M Mukai","year":"2020","unstructured":"Mukai\u00a0M, Kurihara\u00a0Y, Ito\u00a0Y et\u00a0al (2020) Successful treatment with secukinumab of three psoriatic patients undergoing dialysis. J\u00a0Dermatol 47:e26\u2013e28","journal-title":"J Dermatol"},{"key":"1283_CR51","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1111\/bcp.13726","volume":"84","author":"F Namour","year":"2018","unstructured":"Namour\u00a0F, Fagard\u00a0L, Van der Aa\u00a0A et\u00a0al (2018) Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a\u00a0selective JAK1 inhibitor. Br J Clin Pharmacol 84:2779\u20132789","journal-title":"Br J Clin Pharmacol"},{"key":"1283_CR52","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2215\/CJN.13091118","volume":"14","author":"SD Navaneethan","year":"2019","unstructured":"Navaneethan\u00a0SD, Shao\u00a0J, Buysse\u00a0J et al (2019) Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol 14:1011\u20131020","journal-title":"Clin J Am Soc Nephrol"},{"key":"1283_CR53","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor\u00a0KL, Mcarthur\u00a0E, Leslie\u00a0WD et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810\u2013818","journal-title":"Kidney Int"},{"key":"1283_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","volume":"29","author":"J Nespoux","year":"2020","unstructured":"Nespoux\u00a0J, Vallon\u00a0V (2020) Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens 29:190\u2013198","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1283_CR55","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen\u00a0SE, Yeomans\u00a0ND, Solomon\u00a0DH et\u00a0al (2016) Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N\u00a0Engl J Med 375:2519\u20132529","journal-title":"N Engl J Med"},{"key":"1283_CR56","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","volume":"48","author":"G Ozen","year":"2021","unstructured":"Ozen\u00a0G, Pedro\u00a0S, Michaud\u00a0K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J\u00a0Rheumatol 48:648\u2013655","journal-title":"J Rheumatol"},{"key":"1283_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1155\/2009\/501345","volume":"23","author":"H Patel","year":"2009","unstructured":"Patel\u00a0H, Barr\u00a0A, Jeejeebhoy\u00a0KN (2009) Renal effects of long-term treatment with 5\u2011aminosalicylic acid. Can J Gastroenterol 23:170\u2013176","journal-title":"Can J Gastroenterol"},{"key":"1283_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.semarthrit.2016.07.016","volume":"46","author":"S Paudyal","year":"2017","unstructured":"Paudyal\u00a0S, Yang\u00a0FM, Rice\u00a0C et al (2017) End-stage renal disease in patients with rheumatoid arthritis. Semin Arthritis Rheum 46:418\u2013422","journal-title":"Semin Arthritis Rheum"},{"key":"1283_CR59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas\u00a0M, Miller\u00a0PD (2021) Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78:582\u2013589","journal-title":"Am J Kidney Dis"},{"key":"1283_CR60","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, Filippatos\u00a0G, Agarwal\u00a0R et\u00a0al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N\u00a0Engl J Med 385:2252\u20132263","journal-title":"N Engl J Med"},{"key":"1283_CR61","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bcp.12098","volume":"76","author":"F Puisset","year":"2013","unstructured":"Puisset\u00a0F, White-Koning\u00a0M, Kamar\u00a0N et al (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76:734\u2013740","journal-title":"Br J Clin Pharmacol"},{"key":"1283_CR62","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker\u00a0PM, Macfadyen\u00a0JG, Glynn\u00a0RJ et al (2018) Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J\u00a0Am Coll Cardiol 71:2405\u20132414","journal-title":"J Am Coll Cardiol"},{"key":"1283_CR63","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jbmr.4235","volume":"36","author":"DE Robinson","year":"2021","unstructured":"Robinson\u00a0DE, Ali\u00a0MS, Pallares\u00a0N et al (2021) Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J\u00a0Bone Miner Res 36:820\u2013832","journal-title":"J Bone Miner Res"},{"key":"1283_CR64","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080","journal-title":"Lancet"},{"key":"1283_CR65","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag\u00a0KG, Petersen\u00a0J, Brandi\u00a0ML et\u00a0al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N\u00a0Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1283_CR66","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato\u00a0M, Inaba\u00a0M, Yamada\u00a0S et\u00a0al (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J\u00a0Bone Miner Metab 39:1082\u20131090","journal-title":"J Bone Miner Metab"},{"key":"1283_CR67","first-page":"270","volume":"15","author":"H Schiffl","year":"2002","unstructured":"Schiffl\u00a0H, Lang\u00a0SM, Fischer\u00a0R (2002) Stopping smoking slows accelerated progression of renal failure in primary renal disease. J\u00a0Nephrol 15:270\u2013274","journal-title":"J Nephrol"},{"key":"1283_CR68","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman\u00a0AM, Bain\u00a0SC, Bakris\u00a0GL et al (2022) Effect of the glucagon-like peptide\u20111 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575\u2013585","journal-title":"Circulation"},{"key":"1283_CR69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak\u00a0MG, Tummalapalli\u00a0SL, Boulware\u00a0LE et\u00a0al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a\u00a0kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99:34\u201347","journal-title":"Kidney Int"},{"key":"1283_CR70","first-page":"1372859","volume":"2017","author":"K Stahl","year":"2017","unstructured":"Stahl\u00a0K, Duong\u00a0M, Schwarz\u00a0A et\u00a0al (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859","journal-title":"Case Rep Nephrol"},{"key":"1283_CR71","first-page":"2035","volume":"32","author":"T Tokoroyama","year":"2017","unstructured":"Tokoroyama\u00a0T, Ando\u00a0M, Setoguchi\u00a0K et\u00a0al (2017) Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a\u00a0large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 32:2035\u20132042","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR72","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ndt\/gfab308","volume":"37","author":"PU Torres","year":"2022","unstructured":"Torres\u00a0PU, Troya\u00a0MI, Dauverge\u00a0M et al (2022) Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought. Nephrol Dial Transplant 37:613\u2013616","journal-title":"Nephrol Dial Transplant"},{"key":"1283_CR73","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/1346-8138.12903","volume":"42","author":"Y Umezawa","year":"2015","unstructured":"Umezawa\u00a0Y, Hayashi\u00a0M, Kikuchi\u00a0S et\u00a0al (2015) Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J\u00a0Dermatol 42:731\u2013734","journal-title":"J Dermatol"},{"key":"1283_CR74","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","volume":"178","author":"AB Vargas-Santos","year":"2018","unstructured":"Vargas-Santos\u00a0AB, Peloquin\u00a0CE, Zhang\u00a0Y et al (2018) Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 178:1526\u20131533","journal-title":"JAMA Intern Med"},{"key":"1283_CR75","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/CJN.18501120","volume":"16","author":"EYF Wan","year":"2021","unstructured":"Wan\u00a0EYF, Yu\u00a0EYT, Chan\u00a0L et al (2021) Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin J Am Soc Nephrol 16:898\u2013907","journal-title":"Clin J Am Soc Nephrol"},{"key":"1283_CR76","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C, Inzucchi\u00a0SE, Lachin\u00a0JM et\u00a0al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N\u00a0Engl J Med 375:323\u2013334","journal-title":"N Engl J Med"},{"key":"1283_CR77","first-page":"745","volume":"117","author":"G Weckmann","year":"2020","unstructured":"Weckmann\u00a0G, Chenot\u00a0JF, Stracke\u00a0S (2020) The management of non-dialysis-dependent chronic kidney disease in primary care. Dtsch Arztebl Int 117:745\u2013751","journal-title":"Dtsch Arztebl Int"},{"key":"1283_CR78","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00393-014-1480-2","volume":"74","author":"SM Weiner","year":"2015","unstructured":"Weiner\u00a0SM, Bergner\u00a0R (2015) Dosage and toxicity of antirheumatic drugs in renal insufficiency. Z\u00a0Rheumatol 74:300\u2013309","journal-title":"Z Rheumatol"},{"key":"1283_CR79","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/a-1121-8852","volume":"45","author":"SM Weiner","year":"2020","unstructured":"Weiner\u00a0SM, Waldherr\u00a0R (2020) Value of renal biopsy in lupus nephritis. Akt Rheumatol 45:319\u2013327","journal-title":"Akt Rheumatol"},{"key":"1283_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Stef\u00e1nsson\u00a0BV, Jongs\u00a0N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a\u00a0prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22\u201331","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1283_CR81","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton\u00a0PK, Carey\u00a0RM, Aronow\u00a0WS et\u00a0al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension 71:e13\u2013e115","journal-title":"Hypertension"},{"key":"1283_CR82","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W et\u00a0al (2018) 2018 practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH\/ESC task force for the management of arterial hypertension. J\u00a0Hypertens 36:2284\u20132309","journal-title":"J Hypertens"},{"key":"1283_CR83","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Wright\u00a0JT Jr., Williamson\u00a0JD, Whelton\u00a0PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"1283_CR84","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1744-9987.12867","volume":"24","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto\u00a0J, Nakazawa\u00a0D, Nishio\u00a0S et\u00a0al (2020) Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study. Ther Apher Dial 24:146\u2013153","journal-title":"Ther Apher Dial"},{"key":"1283_CR85","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR et\u00a0al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med 386:316\u2013326","journal-title":"N Engl J Med"},{"key":"1283_CR86","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1681\/ASN.2018040405","volume":"29","author":"S Zewinger","year":"2018","unstructured":"Zewinger\u00a0S, Rauen\u00a0T, Rudnicki\u00a0M et al (2018) Dickkopf\u20113 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J\u00a0Am Soc Nephrol 29:2722\u20132733","journal-title":"J Am Soc Nephrol"},{"key":"1283_CR87","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1681\/ASN.2013050482","volume":"25","author":"S Zewinger","year":"2014","unstructured":"Zewinger\u00a0S, Speer\u00a0T, Kleber\u00a0ME et\u00a0al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J\u00a0Am Soc Nephrol 25:1073\u20131082","journal-title":"J Am Soc Nephrol"},{"key":"1283_CR88","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/0886022X.2021.1920427","volume":"43","author":"Y Zhang","year":"2021","unstructured":"Zhang\u00a0Y, Li\u00a0JJ, Wang\u00a0AJ et\u00a0al (2021) Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients. Ren Fail 43:811\u2013820","journal-title":"Ren Fail"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01283-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T12:06:07Z","timestamp":1670501167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01283-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.M.\u00a0Weiner hat im Rahmen von Vortr\u00e4gen Honorare der Firmen Abbott, AMGEN, BMS, MSD, Novartis, Otsuka, Pfizer, Roche und USB erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}